Atrium Therapeutics, Inc. (RNA) Stock Forecast
RNA analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 4 analysts
- Price target
- $25.00 average of analyst targets
- Upside to target
- +225.9% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-1.70
- 52-week range
- $7.67 – $16.54
RNA analyst ratings
4 analystsNumber of analysts at each rating.
RNA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RNA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.67 | −$0.67 | −$0.67 | — | — | 1 |
| Current fiscal year (2026) | −$3.61 | −$3.61 | −$3.61 | −$4.97 | +8.0% | 1 |
| Next fiscal year (2027) | −$6.39 | −$6.39 | −$6.39 | −$3.61 | −77.0% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RNA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $11.2M | $0 | $15.0M | — | 4 |
| Current fiscal year (2026) | $34.4M | $22.6M | $39.6M | +84.5% | 4 |
| Next fiscal year (2027) | $2.0M | $0 | $8.0M | −94.2% | 4 |
RNA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RNA revenue: reported and forecast
RNA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.70 | −$0.67 | −$0.67 | −$0.67 | −$0.67 | −4.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$3.59 | −$4.55 | −$4.55 | −$4.55 | −$3.61 | +0.6% | 0 up · 1 down |
| Next fiscal year (2027) | −$5.85 | −$8.06 | −$8.06 | −$8.06 | −$6.39 | +9.2% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RNA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RNA beat in 5 of 12.
What analysts expect from RNA
4 analysts cover Atrium Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $25.00, 225.9% above the latest close of $7.67. Analysts expect earnings of −$3.61 per share for 2026, +8.0% from a year earlier. For 2027 the average estimate is −$6.39 per share on revenue of $2.0 million. Atrium Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: RNA income statement, RNA key metrics, RNA chart. See the RNA stock overview for the latest quote and news.
RNA forecast FAQ
What is Atrium Therapeutics's price target?
The average analyst price target for Atrium Therapeutics is $25.00, 225.9% above the latest close of $7.67.
Is Atrium Therapeutics a buy, hold or sell?
Of 4 analysts covering Atrium Therapeutics, 4 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Atrium Therapeutics's EPS forecast?
Analysts forecast −$3.61 per share for 2026 (range −$3.61 to −$3.61); for 2027 the estimate is −$6.39.
What is Atrium Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $34.4 million, growth of 84.5%; for 2027 it is $2.0 million.
When does Atrium Therapeutics report earnings?
Atrium Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026; the EPS estimate is $-1.70.
Does Atrium Therapeutics usually beat earnings estimates?
Atrium Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.